bluebird bio Tender Offer Extended by Carlyle and SK Capital to April 18, 2025
Deal News | Apr 03, 2025 | The Carlyle Group
Carlyle and SK Capital have extended the deadline for their tender offer to acquire bluebird bio, pushing it to April 18, 2025, from the previous expiration date of April 4, 2025. The extension allows further time to satisfy remaining conditions, particularly obtaining necessary regulatory approvals. Approximately 65,120 shares of bluebird were tendered as of April 2, 2025. Founded in 2010, bluebird bio is a leader in gene therapy, boasting FDA approvals for three therapies in a span of two years. Carlyle is a global investment firm, and SK Capital focuses on the life sciences sector. The offer is subjected to conditions outlined in the Offer to Purchase and Schedule TO filed with the SEC. Investors are advised to read the documents carefully before deciding on their shares.
Sectors
- Biotechnology
- Private Equity
- Investment Banking
Geography
- United States – Both bluebird bio and the acquiring entities are based in the United States, with the tender offer and regulatory processes occurring under U.S. jurisdiction.
- Global – Carlyle operates globally, impacting various continents, reflecting the potential global influence of the acquisition.
Industry
- Biotechnology – The article focuses on bluebird bio, a leader in gene therapy development and commercialization.
- Private Equity – Carlyle and SK Capital are private equity firms orchestrating the acquisition of bluebird bio.
- Investment Banking – The involvement of financial transactions, including the tender offer and regulatory filings, falls under this industry.
Financials
- 65,120 shares – The number of bluebird bio shares that have been validly tendered as of the given date.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| bluebird bio, Inc. | Target Company | Company | A leading gene therapy company with FDA-approved treatments, specializing in severe genetic diseases. |
| Carlyle Group | Acquiring Company | Company | A global investment firm with deep industry expertise and significant assets under management. |
| SK Capital Partners | Acquiring Company | Company | A private investment firm focusing on life sciences and specialty materials sectors. |
| Beacon Merger Sub, Inc. | Bidding Entity | Company | A subsidiary entity involved in the tender offer to acquire bluebird bio. |
| Equiniti Trust Company, LLC | Depositary | Company | The firm handling the tendered bluebird shares. |